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Left ventricular assist devices (LVADs) have consistently and 
successfully improved mortality associated with end-stage heart 
failure. However, the definition of an “optimal” outcome post 
LVAD as a benchmark remains debatable. We retrospectively 
examined patients in the Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) between 2012 and 
2016 to assess 1 year post-LVAD “optimal outcome” defined as 
a patient who was alive on device or transplanted, New York 
Heart Association functional class I/II, had no more than 2 hos-
pitalizations at year 1, and no major adverse event. We identi-
fied the features predicting a nonoptimal outcome at 1 year. 
Finally, we focused on 3 years outcomes in patients implanted 
as destination therapy. Of the 12,566 patients in INTERMACS 
who received an LVAD, only 3,495 (27.8%) met our definition 
of optimal LVAD outcome at 1 year. These patients tended to 
be younger, male, and were four times more likely to be sup-
ported as bridge to transplantation. For those with optimal out-
come at year 1, their chances of long-term survival were better 
than those who were alive at year 1, but did not meet criteria 
for an optimal outcome. In the destination therapy population, 
only 14% of patients met the definition of an optimal outcome 
at 3 years. Despite significantly improved survival in patients 
with end-stage heart failure treated with LVAD therapy, ma-
jority patients had nonoptimal outcomes at 1 and 3 years post 
implant, by our definition. There is a pressing need to create a 
benchmark to define optimal outcomes post LVAD, both in our 
clinical trials and practice. ASAIO Journal 2020; XX:00–00.
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The field of mechanical circulatory support has made tremen-
dous progress in the past 15 years, creating a paradigm shift in 
the management of patients with end-stage heart failure (HF).1,2 
The survival of patients receiving continuous-flow left ventricular 
assist devices (LVADs) is 83% at 1 year, with a 5 years survival of 
46%.3 Although morbidity associated with LVADs, as defined by 
the burden of pump-associated adverse events (AE) and hospi-
talizations, has decreased significantly, it remains high. Infection 
and bleeding are the most frequent AEs, although neurologic 
dysfunction and multisystem organ dysfunction are the two most 
common causes of death in the first year of implant.3
Historically, LVAD clinical trial end points have focused on 
survival to demonstrate the pump’s ability to improve outcomes 
in patients with end-stage HF compared with optimal medical 
therapy.1,4 In contrast, contemporary trials have incorporated 
combined end points, which include measures of survival, free 
of a limited number of serious AEs. The Multicenter Study of 
MagLev Technology in Patients Undergoing Mechanical Cir-
culatory Support Therapy with HeartMate 3 (MOMENTUM 3) 
trial’s composite primary end point was survival free of device 
replacement or stroke.2 Similarly, the Ventricular Assist System 
as Destination Therapy of Advanced Heart Failure (ENDUR-
ANCE) trial had a primary composite end point of 2 years 
survival free from disabling stroke or device removal for mal-
function or failure.4 Despite the more strict definition of suc-
cess for these trials, the field continues to debate whether these 
composite end points truly quantify the burden from the con-
stellation of AEs on a patient’s quality of life. Published reports 
from LVAD clinical sites continue to report that less than one in 
three LVAD patients can be categorized as a “success,” albeit 
by varying definitions.5 As we make progress in understanding 
the impact LVADs have on patients, it is important to establish 
a reliable benchmark of “optimal outcomes” to allow for explo-
ration of goals of care and informed/shared decision making.6
Several prior studies have examined outcomes on LVAD 
support with the aim to define optimal outcomes.5,7,8 Anwer 
and colleagues defined success following LVAD implant on 
survival at 2 years, New York Heart Association (NYHA) func-
tional class, AE burden and frequency of hospital readmission 
at 1 year.8 These studies have been limited to a single site, 
focusing on either pump technology or device strategy. The 
purpose of our analysis is to examine optimal outcomes at 1 
and 3 years post continuous-flow LVADs in a large, national, 
real-world registry using Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) data.
Methods
Study Population
We sought to develop a definition of success that included 
current generation LVADs with a minimum of 1 year of fol-
low-up and up to 3 years of follow-up for those implanted 
as destination therapy (DT). We queried the INTERMACS 
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database and included all patients implanted with a continu-
ous-flow LVAD between 2012 and 2016. Total artificial heart 
recipients and recipients of an isolated right ventricular assist 
device (RVAD) were excluded from this study. Of note, the 
INTERMACS registry only includes FDA-approved devices and 
excludes patients enrolled in the investigational arm of new 
device clinical regulatory trials. This manuscript was prepared 
using the INTERMACS research materials obtained from the 
National Heart, Lung, and Blood Institute Biological Specimen 
and Data Repository Information Coordinating Center and 
does not necessarily reflect the opinions or views of INTER-
MACS or National Heart, Lung, and Blood Institute. Waiver 
of informed consent was provided by the Institutional Review 
Board (IRB) at Carnegie Mellon University, Pittsburgh. Patient 
consent for INTERMACS is dictated by local IRB pursuant to 
the individual IRB agreements.
Defining Optimal Outcomes
Based on a modified definition provided by Anwer8 and 
expert opinion of LVAD clinicians, an optimal outcome was 
defined as meeting all four of the following criteria at 1 year 
postimplant: 1) alive or transplanted; 2) NYHA functional class 
I or II at 1 year; 3) no major Aes; and 4) two or fewer hospital-
izations per year. We identified the features predicting a non-
optimal outcome using Cox regression and then compared the 
outcomes in patients undergoing LVAD implant as bridge to 
transplantation (BTT) versus DT as well as by gender at 1 year. 
Finally, we identified optimal outcomes post LVAD at 3 years, 
with focus on DT patients.
Major AEs were defined as those requiring unplanned hos-
pitalization. These include gastrointestinal bleeding requiring 
transfusion(s), major infection, stroke, right HF requiring an 
unplanned RVAD, or pump thrombosis, as defined in INTER-
MACS version 5.0. Driveline infections (cellulitis, superficial 
infection) or non-LVAD-related infections treated only as an 
outpatient were not considered major AEs. However, if a drive-
line infection required hospitalization, intravenous antibiot-
ics, or surgical debridement, then they were included under 
major AE. Likewise, hospital admission for issues not related 
to the LVAD or the LVAD surgery, (e.g., hospitalization for sub-
therapeutic international normalized ratio or bridging, etc.) 
were considered “minor” events and only counted toward the 
number of hospitalizations for our outcome analyses. Patients 
were censored at the time of their earliest “nonoptimal” event, 
whether major AE or third hospitalization to avoid duplication 
of AE. If a patient underwent emergent cardiac transplantation 
due to a pump-related AE, that outcome was categorized as 
nonoptimal. Similarly, pump explant for AEs were also counted 
as nonoptimal while those explanted for myocardial recovery 
were categorized as optimal. For RVADs to be considered an 
AE, they had to fall under “RVAD following an LVAD” or read-
mission after index hospitalization during which an RVAD was 
implanted. A planned RVAD at the time of LVAD implant was 
not counted as a major AE.
Statistical Analysis
Continuous variables were expressed as mean ± standard 
deviation, and categorical data were expressed as numbers 
and percentages. We compared the optimal patient population 
to the nonoptimal to identify key differentiating features in their 
preoperative data. We then applied backward Cox regression 
to identify variables that were predictive of the optimal LVAD 
outcome. Statistical significance was set at p value < 0.05. All 
analyses were performed using SPSS (SPSS, Inc., Chicago)
Results
Of the 12,566 patients in INTERMACS who received a con-
tinuous-flow LVAD, 3,495 (27.8%) met the definition of op-
timal LVAD outcome at 1 year (Figure 1). Of those with an 
optimal outcome, 778 underwent elective cardiac transplan-
tation, 40 were explanted for myocardial recovery, and 2,677 
patients remained alive and well at 1 year on LVAD support. 
Of the 9,070 of patients who had a nonoptimal outcome at 1 
year, 2,070 patients died, 2,454 patients had at least 1 major 
AE, 2,726 patients had three or more hospitalizations, and an 
additional 452 patients failed to achieve a NYHA I or II. Within 
our study group, the most common AEs at 1 year were infec-
tion (31%), bleeding (18%), stroke (11%), and pump throm-
bosis (7%). During this period, the vast majority of patients 
received either the HeartMate II device (Abbott, Abbott Park, 
IL) or HeartWare HVAD (Medtronic, MN).
Figure 1. Sankey diagram representing outcomes of INTERMACS patients at 1 year post LVAD implantation. The width of the flow arrows 
is shown proportionally to the outcome. NYHA, New York Heart Association; AE, adverse event; Rehosp, rehospitalization.
Copyright © ASAIO 2020
 OUTCOMES WITH LVAD 3
Characteristics of Those With and Without 
an Optimal Outcome at 1 Year
Baseline characteristics and demographics of those with 
and without an optimal outcome on LVAD support at 1 year 
are shown in Table 1. Patients with an optimal outcome were 
younger, more likely to be male, and were four times more 
likely to be supported as a BTT. Patients classified with a non-
optimal outcome on LVAD support had higher burdens of pre-
operative comorbidities (including diabetes and renal disease) 
and were more likely to be INTERMACS profiles 1–2 before 
LVAD implant. Although device strategy (DT vs. BTT) was un-
derstandably highly impactful, device type (axial flow vs. cen-
trifugal flow), race, and social demographics did not correlate 
with outcome. From multivariate analysis, predictors of an op-
timal outcome 1 year after LVAD implant included BTT device 
strategy, absence of previous cardiac operations, absence of 
preoperative shock (3–7 INTERMACS profile), no RVAD at time 
of LVAD implant, absence of chronic kidney disease, male 
gender, younger age, and higher hemoglobin (Figure 2).
Correlates of Success on Long-term LVAD Support
In the INTERMACS cohort, survival at 3 years was 66%. 
However, only 22% of patients met the definition of an op-
timal outcome at 3 years. Most patients who were categorized 
as optimal at year 1 remained optimal at year 3. When we re-
stricted the analysis to those alive on device support at 1 year, 
patients with an optimal outcome at year 1 (NYHA functional 
class I or II with no major AEs and ≤ two hospitalizations) had 
a much higher long-term probability of survival compared with 
those who had a nonoptimal outcome at year 1 (p < 0.0001) 
(Figure 3). However, as support duration increased, morbidity 
had a disproportionate impact on therapeutic success.
Impact of Device Strategy on Outcome
Survival at 1 year in the DT and BTT groups was 79% and 
87%, respectively. An optimal outcome was achieved in 24% 
of DT and 31% of BTT at 1 year (Figure 4). At the time of im-
plant, 5,906 (47%) patients were designated as DT. Of them, 
Table 1.  Baseline Characteristics of LVAD Patients Classified Based on Optimal vs. Nonoptimal Outcome.
Patient Characteristic
Full Cohort  
(n = 12,566)
Optimal Outcome  
(n = 3,495)
Not-Optimal Outcome  
(n = 9,071) p
Age, mean ± SD 57 (13) 55 (13) 58 (13) <0.001
Male (%) 9,851 (78.5) 2,833 (81.2) 7,018 (77.5) <0.001
Race, white (%) 8,351 (66.5) 2,294 (65.6) 6,057 (66.8) 0.24
BMI (median [range]) 28.6 (6.7) 28.1 (6.5) 28.7 (6.9) 0.01
Heart rate, mean ± SD 89 (17) 90 (18) 89 (17) 0.001
Systolic blood pressure, mean ± SD 106 (16) 105 (16) 106 (16) 0.03
Diastolic blood pressure, mean ± SD 65 (11) 65 (11) 65 (11) 0.31
Destination therapy (%) 5,843 (46.5) 1,421 (11.3) 4,422 (48.8) <0.001
Centrifugal flow pump (%) 3,070 (24.4) 849 (24.3) 2,221 (24.5) 0.81
RVAD and LVAD (%) 478 (3.8) 96 (2.8) 382 (4.2) <0.001
NYHA 3–4 (%) 11,841 (94.2) 3,282 (93.9) 8,559 (94.4) 0.33
INTERMACS 1–2 (%) 6,436 (51.2) 1,699 (48.6) 4,737 (52.2) <0.001
Comorbidities and medical history
 Atrial fibrillation (%) 1,074 (8.5) 275 (7.9) 799 (8.8) 0.52
 Ischemic etiology (%) 5,996 (47.7) 1,505 (43) 4,491 (49.5) <0.001
 Severe diabetes (%) 478 (3.9) 104 (3) 374 (4.2) 0.002
 Chronic kidney disease (%) 983 (7.9) 188 (5.5) 795 (8.9) <0.001
 Cancer (%) 483 (3.8) 123 (3.5) 360 (4) 0.24
 Peripheral vascular disease (%) 248 (2) 40 (1.2) 208 (2.3) <0.001
 History of CABG (%) 2,606 (20.7) 560 (16) 2,046 (22.6) <0.001
 ICD (%) 9,999 (80.1) 2,690 (77.4) 7,309 (81.1) <0.001
Social factors
 Married (%) 7,847 (62.4) 2,188 (62.6) 5,659 (62.4) 0.81
 College education (%) 4,505 (35.9) 1,271 (36.4) 3,234 (35.6) 0.44
 Current smoker (%) 566 (4.6) 148 (4.3) 418 (4.7) 0.34
 Drug abuse (%) 396 (3.2) 116 (3.4) 280 (3.1) 0.52
 Alcohol abuse (%) 350 (2.8) 94 (2.7) 256 (2.9) 0.66
Preoperative laboratory values, mean ± SD
 Sodium, mmol/L 135 (4.7) 135 (4.7) 135 (4.9) 0.038
 BUN, mg/dL 29 (18) 27 (16) 30 (19) <0.001
 Creatinine, mg/dL 1.4 (0.7) 1.3 (0.6) 1.4 (0.7) <0.001
 Albumin, g/dL 3.4 (0.6) 3.4 (0.6) 3.4 (0.7) 0.35
 Total bilirubin, mg/dL 1.4 (1.9) 1.4 (1.7) 1.4 (2.2) 0.008
 ALT, IU/L 68 (228) 69 (256) 68 (222) 0.84
 AST, IU/L 56 (209) 55 (240) 58 (227) 0.38
 INR 1.3 (0.4) 1.3 (0.4) 1.3 (0.4) 0.004
 Cholesterol, mg/dL 134 (158) 136 (168) 132 (148) 0.81
 WBC count, K/µL 8.5 (3.8) 8.5 (3.7) 8.7 (4.1) 0.007
 Hemoglobin, d/dL 11.3 (2.1) 11.5 (2.2) 11.1 (2.1) 0.85
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery 
bypass graft; ICD, implantable cardiac defibrillator; INR, international normalized ratio; INTERMACS, Interagency Registry for Mechanically 
Assisted Circulatory Support; LVAD, left ventricular assist device; NYHA, New York Heart Association; RVAD, right ventricular assist device; 
WBC, white blood cell.
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2,898 patients had 3 years outcomes data in INTERMACS 
within the study period. The proportion of morbidity and mor-
tality contributing to the end point is shown in Figure 5. Of DT 
patients with at least 3 years of follow-up, only 14% had an 
optimal outcome, with majority of nonoptimal outcomes rep-
resenting death. Adjusted correlates associated with failure to 
achieve optimal outcome post LVAD at 1 year for each group 
are shown in Table 2. Outcomes for patients on DT support 
were impacted by comorbidities present pre-LVAD such as pe-
ripheral vascular disease and kidney disease.
Impact of Gender on Outcome
Within INTERMACS, 79% of LVAD recipients were male. 
One-year survival was 84% for males and 83% for females, and 
67% and 65% at 3 years, respectively. An optimal outcome was 
achieved in 29% of men and 24% of women at 1 year, and in 
23% of men and 18% of women at 3 years (Figure 6). Table 3 
shows the multivariable correlates associated with failure to 
achieve an optimal outcome post LVAD at 1 year, based on pa-
tient gender. Of the risk correlates, right ventricular failure por-
tended a twofold adjusted risk of treatment failure.
Figure 2. Forest plot showing impact of pre and peri operative variables on nonoutcomes in LVAD patients at 1 year postimplant. ECMO, 
extra corporeal membrane oxygenation; IV, intravenous; BMI, body mass index; RVAD, right ventricular assist device; INTERMACS, Inter-
agency Registry for Mechanically Assisted Circulatory Support; ICD, implantable cardiac defibrillator; INR, international normalized ratio.
Figure 3. Analysis of patients alive on support at 1 year. Patients at time point “0” in months on x-axis were patients who had survived to 
the 1 year mark, in blue with optimal outcome and in red with a nonoptimal outcomes as defined.
Copyright © ASAIO 2020
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Discussion
Based on the criteria defining an optimal outcome used 
in this study, only 28% of LVAD recipients in INTERMACS 
achieved an optimal outcome 1-year postimplant, dropping to 
22% at 3 years. AEs and deaths contributed equally to patients’ 
inability to achieve success on LVAD support. Within the DT 
group, only 24% and 14% patients had an optimal end point 
at 1 and 3 years, respectively. This is particularly relevant given 
the increasing frequency of DT implants (from 35% in 2010 to 
52% in 20163 and the expectation that changes in U.S. organ 
allocation are expected to further skew LVAD indication to-
ward DT support.
While the survival benefit of LVADs for HF are substan-
tial, the field is moving away from survival alone to survival 
free of major AEs as the metric for a successful outcome. 
The MOMENTUM 3 trial looked at a composite primary end 
point—patients alive, free of device replacement and stroke. 
An additional “living well on an LVAD” end point was de-
fined as alive at 6 months with satisfactory functional capacity 
(NYHA I/II or 6- min walk test > 300 m) and a Kansas City 
Cardiomyopathy Questionnaire (KCCQ) score >50.7 The end 
point was achieved in 63% and 68% of patients on HM3 and 
HMII support, respectively. Similarly, the ENDURANCE trial 
had the primary end point of a composite of 2 years survival 
free from disabling stroke, with the patient alive with the orig-
inally implanted device, having undergone elective trans-
plantation, or with the device explanted because of cardiac 
recovery.4 Clearly a step in the right direction, these end points 
Figure 4. Kaplan-Meier curves of time to optimal outcomes based on device strategy. Patients were censored at time of transplant or 
recovery.
Figure 5. Sankey diagram showing 3 years outcomes of patients undergoing LVAD implant as destination therapy (DT). Only patients who 
were implanted as DT and had 3 years outcomes in INTERMACS during the study period are included.
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underscore the need to define an optimal outcome with an 
LVAD from the perspective of patients, their caregivers, as well 
as healthcare providers.
We assessed a real-world population represented in INTER-
MACS, and only 28% of patients were considered a success 
when defined as a composite of survival, number of hospi-
talizations, freedom from all major AEs and improvement in 
symptoms of HF. This is not dissimilar to Anwer et al.’s single-
center report, which demonstrated that only 29% of 278 LVAD 
patients achieved a successful outcome.8 The difference in our 
findings from those reported in clinical trials are multifactorial, 
including greater time at risk for an event (1 year vs. 6 months 
of follow-up) and a sicker patient population than that enrolled 
in trials (more INTERMACS profiles 1–2). In addition, many 
clinical trials utilize KCCQ to assess quality of life. However, 
KCCEQ, which focuses primarily on HF related symptoms, has 
its inherent limitations, potentially failing to capture the im-
pact of hospitalizations, challenges with device management, 
bleeding, etc. Even using survival and a KCCQ >45 as their 
end point for success, Arnold et al. reported that nearly one in 
three DT LVAD recipients failed to have an optimal outcome 
in INTERMACS.5
In our analysis, having a nonoptimal 1 year outcome (con-
ditional to survival) impaired the likelihood of long-term sur-
vival. When we categorized patients by device intent and sex, 
important differential outcomes were noted. For DT patients 
that had 3 years outcomes data included, the vast majority of 
nonoptimal outcomes were accounted for by mortality. Patients 
on DT LVAD support suffer from underlying comorbidities as 
well as pump-related AEs. Women were less likely than men to 
achieve VAD optimal outcomes. While DT patients often have 
multiple comorbidities, which contribute to less than ideal out-
comes, the factors impeding successful support in women can-
not be fully elucidated from this analysis.
Our findings underscore the importance of defining an op-
timal outcome so we can better inform the discussion of elicit-
ing an individual patients’ goals of care with LVAD therapy.9 
Providing information on the range of outcomes is important 
when considering LVAD therapy.10 Many patients view sur-
vival as an important factor in decision making, but quality 
of life and risk of AEs are often equally important. Particularly 
among elderly patients ineligible for transplantation, a reason-
able quality of life may be an even more important treatment 
goal than survival.11 Although the LVAD-related AEs are often 
Table 2.  Adjusted Correlates Associated with Failure to Achieve Optimal Outcome Post LVAD at 1 Year Based on Device Strategy.
Destination Therapy Bridge to Transplantation
 Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age, per y 1.005 (1.002-1.008) 0.001 1.007 (1.004-1.010) <0.001
Female gender 1.135 (1.046-1.231) 0.002 1.208 (1.118-1.306) <0.001
Previous cardiac operations 1.152 (1.073-1.237) <0.001 1.195 (1.112-1.284) <0.001
Events during hospitalization 1.085 (1.006-1.17) 0.03 1.098 (1.021-1.182) 0.01
ECMO during hospitalization 1.237 (1.029-1.488) 0.02 1.236 (1.064-1.435) 0.005
Dialysis within 48 h of implant 1.825 (1.441-2.313) <0.001 1.389 (1.07-1.776) 0.009
RVAD within 48 h of implant 1.773 (1.169-2.689) 0.007 – –
INTERMACS 1–2 1.129 (1.05-1.214) 0.001 1.121 (1.042-1.207) 0.002
Chronic kidney disease 1.115 (1.013-1.227) 0.03 – –
Peripheral vascular disease 1.166 (0.989-1.375) 0.07 – –
BMI, per kg/m2 1.007 (1.003-1.012) 0.001 1.007 (1.004-1.012) 0.01
Hemoglobin, per g/dL 0.976 (0.959-0.992) 0.004 0.961 (0.945-0.977) <0.001
BUN, per mg/dL 1.003 (1.001-1.005) <0.001 1.003 (1.001-1.004) 0.001
–, not applicable; BMI, body mass index; BUN, blood urea nitrogen; ECMO, extra corporeal membrane oxygenation; INTERMACS, 
Interagency Registry for Mechanically Assisted Circulatory Support; RVAD, right ventricular assist device.
Figure 6. Kaplan-Meier curves of time to optimal outcomes based on gender. Patients were censored at time of transplant or recovery.
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effectively addressed with medical intervention, major com-
plications or progression of underlying noncardiac comorbidi-
ties (cancer, renal disease, frailty) still commonly force patients 
and caregivers to confront the difficult decision of continued 
survival with poor quality of life on prolonged circulatory sup-
port.12 Consequently, integrating quality-of-life outcomes into 
the definition of a poor outcome is particularly relevant in this 
patient population.5
Although end-stage HF comprises 5% (approximately 
350,000 patients/y in the United States) of HF population, 
the uptake of adult patients on LVAD support is limited to less 
than 30,000 pumps to date.3 There are, of course, multiple fac-
tors contributing to that, but in order for LVAD therapy to be 
fully embraced as the treatment for end-stage HF (in addition 
to transplantation), we will need to continue to expand our 
vision beyond survival. This will be especially relevant as the 
field moves towards discussing permanent support for indi-
viduals who are less ill (INTERMACS profiles 4–7). Informed 
consent for an LVAD in ambulatory patients with end-stage HF 
will need to be balanced against a potentially nonoptimal out-
come for these noncritically ill patients. Understanding what 
is important to patients is essential for providers of patients 
considering LVAD therapy and can help elicit what an op-
timal outcome may be for that patient.13 In order to engage 
patients and facilitate shared decision making around these 
issues, decision support tools such as decision aids can be 
used. Evidence-based decision aids allow for standardization 
of information, a clear explanation of risks, benefits, and al-
ternative options, and the facilitation of informed discussions 
with providers.14 By embracing a composite definition of an 
optimal outcome—however defined—providers can more 
consistently and accurately engage patients in shared decision 
making, grounded in a thorough review of expected risks and 
benefits.15
Limitations
Our study has several limitations. The composite end 
point chosen to define an optimal outcome has been re-
ported in a single-center analysis but has not been vali-
dated as an end point. We do not intend this definition to 
be considered as definitive or necessarily a clinical trial end 
point. However, the end point used herein is a focus point 
to engage the LVAD community in the discussion to create 
one, and to challenge ourselves to meet that standard. Not 
all complications experienced by patients are associated 
with the same impact on their perceived optimal quality 
of life. For example, the impact of stroke or device ex-
change cannot be equivocated to multiple hospitalizations 
for minor AEs. Although most patients value quality of life, 
some patients may consider survival with a poor quality of 
life an acceptable outcome, especially given the alternative. 
Such patients, although classified as “nonoptimal” by our 
definition may, in fact, have an acceptable outcome in their 
perception. NYHA class is assessed at 1 year and not over 
the period leading up to 1 year. Additionally, NYHA class is 
a subjective assessment, subject to debate as a measure of 
patient summary in LVAD patients. We did not include any 
quality-of-life questionnaire data into our analysis. Given 
that the INTERMACS registry duration we analyzed did not 
include HeartMate 3 devices (MOMENTUM 3 was an on-
going clinical trial at the time), we have not captured data 
on a contemporary pump with improved outcomes, espe-
cially in relation to improved survival and freedom from de-
vice exchange for pump thrombosis. As such, it is likely that 
we may have overestimated the proportion of patients who 
have poor quality of life after LVAD.
Conclusion
Despite an overall trend in improved survival with LVADs in 
recent times, less than one-third of the patients achieved op-
timal health outcomes with this therapy, per our criteria. Given 
that improvements in survival have tracked with technology 
advances, this life-saving technology should increasingly affect 
a large number of patients with end-stage HF. However, pro-
longing life should not be the sole determinant of an optimal 
outcome post LVAD. Future conversations regarding effective-
ness of LVAD therapy with patients or future research address-
ing end points in clinical trials evaluating newer generations 
of LVAD should focus increasingly on composite criteria that 
reflect optimal health.
Table 3.  Adjusted Correlates Associated with Failure to Achieve Optimal Outcome Post LVAD at 1 Year Based on Gender.
Male Female
 Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age 1.007 (1.005-1.010) <0.001 – –
Previous cardiac operation 1.165 (1.101-1.233) <0.001 1.194 (1.067-1.336) 0.002
Events during hospitalization 1.066 (1.004-1.131) 0.03 1.19 (1.067-1.336) 0.002
ECMO during hospitalization 1.241 (1.087-1.418) 0.001 1.366 (1.088-1.715) 0.007
Inotrope therapy 0.90 (0.823-0.985) 0.02 1.285 (1.062-1.556) 0.01
INTERMACS profiles 1–2 1.121 (1.057-1.189) <0.001 1.123 (1.006-1.253) 0.04
Chronic kidney disease 1.114 (1.019-1.219) 0.02 1.188 (0.972-1.451) 0.09
Hemoglobin 0.965 (0.952-0.978) <0.001 0.975 (0.949-1.002) 0.07
BUN, per mg/dL 1.003 (1.001-1.004) <0.001 1.003 (1.0-1.006) 0.4
RVAD within 48 h of implant – – 2.23 (1.288-3.86) 0.04
Systolic BP, per mm Hg – – 1.004 (1.001-1.007) 0.007
PVD 1.203 (1.017-1.424) 0.03 – –
INR 0.923 (0.859-0.992) 0.03 – –
Centrifugal flow 1.075 (1.009-1.146) 0.3 – –
–, not applicable; BP, blood pressure; BUN, blood urea nitrogen; ECMO, extra corporeal membrane oxygenation; INR, international normal-
ized ratio; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; PVD, peripheral vascular disease; RVAD, right 
ventricular assist device.
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